These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 21190039)
41. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Wang Y; Zhang LL; Champlin RE; Wang ML Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675 [TBL] [Abstract][Full Text] [Related]
42. New approaches to therapeutic drug development for childhood cancers. Campbell K; Ma C; DuBois SG Curr Opin Pediatr; 2020 Feb; 32(1):35-40. PubMed ID: 31790026 [TBL] [Abstract][Full Text] [Related]
43. Cabozantinib for relapsed neuroblastoma: Single institution case series. Perisa MP; Storey M; Streby KA; Ranalli MA; Skeens M; Shah N Pediatr Blood Cancer; 2020 Jul; 67(7):e28317. PubMed ID: 32343886 [TBL] [Abstract][Full Text] [Related]
44. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. Sheng J; Srivastava S; Sanghavi K; Lu Z; Schmidt BJ; Bello A; Gupta M J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S26-S42. PubMed ID: 28921644 [TBL] [Abstract][Full Text] [Related]
45. Crizotinib-induced erosive esophagitis in a pediatric patient with neuroblastoma. Lubcke N; Van Camp K J Oncol Pharm Pract; 2019 Apr; 25(3):724-726. PubMed ID: 29357780 [TBL] [Abstract][Full Text] [Related]
46. [New concepts in human oncology: is it possible to use them in veterinary medicine as well?]. Marconato L; Ruess-Melzer K; Buchholz J; Kaser-Hotz B Schweiz Arch Tierheilkd; 2011 Aug; 153(8):351-60. PubMed ID: 21780063 [TBL] [Abstract][Full Text] [Related]
48. Developing novel strategies to target B-cell malignancies. Fowler N; Oki Y Am Soc Clin Oncol Educ Book; 2013; ():366-72. PubMed ID: 23714549 [TBL] [Abstract][Full Text] [Related]
49. Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise. Foluso O; Glick A; Stender M; Jaiyesimi I Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):63-9. PubMed ID: 26775273 [TBL] [Abstract][Full Text] [Related]
50. Small molecule kinase inhibitors as anti-cancer therapeutics. Chahrour O; Cairns D; Omran Z Mini Rev Med Chem; 2012 May; 12(5):399-411. PubMed ID: 22303944 [TBL] [Abstract][Full Text] [Related]
51. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Bellinger AM; Arteaga CL; Force T; Humphreys BD; Demetri GD; Druker BJ; Moslehi JJ Circulation; 2015 Dec; 132(23):2248-58. PubMed ID: 26644247 [TBL] [Abstract][Full Text] [Related]
56. Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia. Kittai AS; Woyach JA Cancer J; 2019; 25(6):428-435. PubMed ID: 31764124 [TBL] [Abstract][Full Text] [Related]
57. Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers. Hwang TJ; Orenstein L; DuBois SG; Janeway KA; Bourgeois FT J Natl Cancer Inst; 2020 Mar; 112(3):224-228. PubMed ID: 31665394 [TBL] [Abstract][Full Text] [Related]
58. Spotlight on chronic lymphocytic leukemia: a Pharma Matters report. D'Souza P; Walker G Drugs Today (Barc); 2014 Jul; 50(7):485-501. PubMed ID: 25101331 [TBL] [Abstract][Full Text] [Related]
59. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia. Khan Y; O'Brien S Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956 [TBL] [Abstract][Full Text] [Related]
60. Tyrosine kinase inhibitors in pediatric malignancies. Skolnik JM; Adamson PC Cancer Invest; 2007; 25(7):606-12. PubMed ID: 17952738 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]